|
|
 Previous Article | Table of Contents | Next Article 
Donor Leukocyte Infusions Are Effective in Relapsed Multiple Myeloma After Allogeneic Bone Marrow Transplantation
H.M. Lokhorst,
A. Schattenberg,
J.J. Cornelissen,
L.L.M. Thomas, and
L.F. Verdonck
From the Department of Haematology, University Hospital Utrecht, Utrecht, The Netherlands; the Department of Haematology, University Hospital, Nijmegen, The Netherlands; the Department of Haematology, Dr. Daniel den Hoed Clinic, Rotterdam, The Netherlands; and the Department of Haematology, Academic Medical Center, Amsterdam, The Netherlands.
Donor leukocyte infusions (DLI) can induce sustained remissions in patients with acute and chronic myeloid leukemia who relapse after allogeneic bone marrow transplantation (allo-BMT). Also, in multiple myeloma (MM), incidental reports have indicated the existence of a graft-versus-myeloma effect (GVM) induced by allo-reactive T cells. We performed a retrospective study in a larger group of MM patients to characterize better the effect, prognostic factors, and toxicity of this new treatment modality. Thirteen patients with relapsed MM after allo-BMT were studied. Patients received a total of 29 DLI with T-cell doses ranging from 1 × 106/kg to 33 × 107/kg. Repetitive courses, sometimes with escalated cell doses, were undertaken in case of no response to or relapse after DLI. Eight of 13 patients responded: 4 patients achieved a partial remission and 4 patients achieved a complete remission. Dose escalation was effective in 3 patients. The time to response was median 6 weeks (range, 4 to 10 weeks). Major toxicities were secondary to acute and chronic graft-versus-host disease (GVHD), which occurred in 66% and 56% of all patients and in 87% and 85% of the responders, respectively. Two responding patients developed fatal BM aplasia. The only prognostic factors for response were a T-cell dose greater than 1 × 108/kg and the occurrence of GVHD. Seven of nine patients developing acute GVHD responded, as compared with only 1 response in the 4 patients without GVHD and 6 of 7 patients with chronic GVHD responded, whereas no response was observed in the 5 patients without chronic GVHD. DLI are effective in a high percentage of patients with relapsed MM after allo-BMT, although it is associated with a high treatment-related toxicity. The dose of T cells used may be important in determining the GVM effect, with the highest probability of response after infusion of more than 1 × 108 T cells. Because the optimal individual dose may vary, patient-adapted therapy consisting of repeated infusions with escalating dose of donor leukocytes until maximum response is achieved may therefore be preferable.
Blood, Vol. 90 No. 10 (November 15), 1997:
pp. 4206-4211
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Qian, J. Xie, S. Hong, J. Yang, L. Zhang, X. Han, M. Wang, F. Zhan, J. D. Shaughnessy Jr, J. Epstein, et al.
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma
Blood,
September 1, 2007;
110(5):
1587 - 1594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ciceri, C. Bonini, S. Marktel, E. Zappone, P. Servida, M. Bernardi, A. Pescarollo, A. Bondanza, J. Peccatori, S. Rossini, et al.
Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation
Blood,
June 1, 2007;
109(11):
4698 - 4707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bellucci, S. Oertelt, M. Gallagher, S. Li, E. Zorn, E. Weller, F. Porcheray, E. P. Alyea, R. J. Soiffer, N. C. Munshi, et al.
Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis
Blood,
March 1, 2007;
109(5):
2001 - 2007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Huff and J. E. Karp
Should MAGE be the rage in myeloma?
Blood,
July 1, 2005;
106(1):
5 - 5.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Rew, K. Peggs, I. Sanjuan, A. R. Pizzey, Y. Koishihara, S. Kawai, M. Kosaka, S. Ozaki, B. Chain, and K. L. Yong
Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24
Clin. Cancer Res.,
May 1, 2005;
11(9):
3377 - 3384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Takahashi and R. W. Childs
Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma
Clin. Cancer Res.,
September 15, 2004;
10(18):
6353S - 6359S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Lokhorst, K. Wu, L. F. Verdonck, L. L. Laterveer, N. W. C. J. van de Donk, M. H. J. van Oers, J. J. Cornelissen, and A. V. Schattenberg
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
Blood,
June 1, 2004;
103(11):
4362 - 4364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Mapara and M. Sykes
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
J. Clin. Oncol.,
March 15, 2004;
22(6):
1136 - 1151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Peggs, K. Thomson, D. P. Hart, J. Geary, E. C. Morris, K. Yong, A. H. Goldstone, D. C. Linch, and S. Mackinnon
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
Blood,
February 15, 2004;
103(4):
1548 - 1556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Maloney, A. J. Molina, F. Sahebi, K. E. Stockerl-Goldstein, B. M. Sandmaier, W. Bensinger, B. Storer, U. Hegenbart, G. Somlo, T. Chauncey, et al.
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
Blood,
November 1, 2003;
102(9):
3447 - 3454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hayashi, T. Hideshima, M. Akiyama, N. Raje, P. Richardson, D. Chauhan, and K. C. Anderson
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes
Blood,
August 15, 2003;
102(4):
1435 - 1442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Renga, P. Pedrazzoli, and S. Siena
Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors
Ann. Onc.,
August 1, 2003;
14(8):
1177 - 1184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Matsui, L. A. O'Mara, and P. M. Allen
Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy
Int. Immunol.,
July 1, 2003;
15(7):
797 - 805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Orsini, R. Bellucci, E. P. Alyea, R. Schlossman, C. Canning, S. McLaughlin, P. Ghia, K. C. Anderson, and J. Ritz
Expansion of Tumor-specific CD8+ T Cell Clones in Patients with Relapsed Myeloma after Donor Lymphocyte Infusion
Cancer Res.,
May 15, 2003;
63(10):
2561 - 2568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Lokhorst, C. M. Segeren, L. F. Verdonck, B. van der Holt, R. Raymakers, M. H.J. van Oers, R. M.Y. Barge, H. C. Schouten, P. H.M. Westveer, M. M.C. Steijaert, et al.
Partially T-Cell-Depleted Allogeneic Stem-Cell Transplantation for First-Line Treatment of Multiple Myeloma: A Prospective Evaluation of Patients Treated in the Phase III Study HOVON 24 MM
J. Clin. Oncol.,
May 1, 2003;
21(9):
1728 - 1733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. I. Marks, R. Lush, J. Cavenagh, D. W. Milligan, S. Schey, A. Parker, F. J. Clark, L. Hunt, J. Yin, S. Fuller, et al.
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation
Blood,
October 16, 2002;
100(9):
3108 - 3114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Perez-Simon, P. D. Kottaridis, R. Martino, C. Craddock, D. Caballero, R. Chopra, J. Garcia-Conde, D. W. Milligan, S. Schey, A. Urbano-Ispizua, et al.
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
Blood,
October 16, 2002;
100(9):
3121 - 3127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bellucci, E. P. Alyea, E. Weller, A. Chillemi, E. Hochberg, C. J. Wu, C. Canning, R. Schlossman, R. J. Soiffer, K. C. Anderson, et al.
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma
Blood,
May 29, 2002;
99(12):
4610 - 4617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-G. Yang, J. Qi, M.-G. Wang, and M. Sykes
Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells
Blood,
May 13, 2002;
99(11):
4207 - 4215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Maloney, B. M. Sandmaier, S. Mackinnon, and J. A. Shizuru
Non-Myeloablative Transplantation
Hematology,
January 1, 2002;
2002(1):
392 - 421.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Corradini, C. Tarella, A. Olivieri, A. M. Gianni, C. Voena, F. Zallio, M. Ladetto, M. Falda, M. Lucesole, A. Dodero, et al.
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies
Blood,
January 1, 2002;
99(1):
75 - 82.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Alyea, E. Weller, R. Schlossman, C. Canning, I. Webb, D. Doss, P. Mauch, K. Marcus, D. Fisher, A. Freeman, et al.
T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect
Blood,
August 15, 2001;
98(4):
934 - 939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Michallet, K. Bilger, F. Garban, M. Attal, A. Huyn, D. Blaise, N. Milpied, P. Moreau, P. Bordigoni, M. Kuentz, et al.
Allogeneic Hematopoietic Stem-Cell Transplantation After Nonmyeloablative Preparative Regimens: Impact of Pretransplantation and Posttransplantation Factors on Outcome
J. Clin. Oncol.,
July 15, 2001;
19(14):
3340 - 3349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Kyle
Update on the Treatment of Multiple Myeloma
Oncologist,
April 1, 2001;
6(2):
119 - 124.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Cutler and J. H. Antin
Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review
Stem Cells,
February 1, 2001;
19(2):
108 - 117.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. M. Lokhorst, A. Schattenberg, J. J. Cornelissen, M. H. J. van Oers, W. Fibbe, I. Russell, N. W. C. J. v. d. Donk, and L. F. Verdonck
Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term Outcome
J. Clin. Oncol.,
August 16, 2000;
18(16):
3031 - 3037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mielcarek, W. Leisenring, B. Torok-Storb, and R. Storb
Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect
Blood,
August 1, 2000;
96(3):
1150 - 1156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Anderson, R. A. Kyle, W. S. Dalton, T. Landowski, K. Shain, R. Jove, L. Hazlehurst, and J. Berenson
Multiple Myeloma: New Insights and Therapeutic Approaches
Hematology,
January 1, 2000;
2000(1):
147 - 165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Massaia, P. Borrione, S. Battaglio, S. Mariani, E. Beggiato, P. Napoli, C. Voena, A. Bianchi, M. Coscia, B. Besostri, et al.
Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy
Blood,
July 15, 1999;
94(2):
673 - 683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Raje, J. Gong, D. Chauhan, G. Teoh, D. Avigan, Z. Wu, D. Chen, S. P. Treon, I. J. Webb, D. W. Kufe, et al.
Bone Marrow and Peripheral Blood Dendritic Cells From Patients With Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Detection of Kaposi's Sarcoma Herpesvirus Gene Sequences
Blood,
March 1, 1999;
93(5):
1487 - 1495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Corradini, C. Voena, C. Tarella, M. Astolfi, M. Ladetto, A. Palumbo, M. T. Van Lint, A. Bacigalupo, A. Santoro, M. Musso, et al.
Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic Cells
J. Clin. Oncol.,
January 1, 1999;
17(1):
208 - 208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Alyea, R. J. Soiffer, C. Canning, D. Neuberg, R. Schlossman, C. Pickett, H. Collins, Y. Wang, K. C. Anderson, and J. Ritz
Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant
Blood,
May 15, 1998;
91(10):
3671 - 3680.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
